Hot Seat: Dr. Nathalie Weitemeyer | Bayern Kapital

Last updated on: 25 Feb, 2026

(Translated with Mistral without further editing)

For 30 years, Bayern Kapital has been supporting innovative companies in their growth and is now one of Germany’s most financially strong state-backed venture capital investors. In this discussion, we look back at the development of Bavaria’s start-up ecosystem, the challenges of capital-intensive deep tech models, and the technological trends that will shape the investment landscape in the future.

Bayern Kapital celebrated its 30th anniversary last year. Looking back, what developments in Bavaria’s start-up ecosystem have shaped you the most over this period, and what does this milestone mean to you personally?

Last year, we celebrated Bayern Kapital’s 30th anniversary, which nearly coincided with my own personal milestone: I have been part of Bayern Kapital for 25 years and have witnessed the evolution of Bavaria’s start-up ecosystem through many phases.
When I started, start-up investments were heavily influenced by the Neuer Markt, which was still at its peak. Shortly afterward, however, it collapsed, and IPOs as an exit strategy played almost no role for a long time, while M&A transactions gained significantly in importance.
Over the years, the market has experienced several highs and lows. What has been confirmed time and again is that new growth cycles follow difficult phases—and truly strong companies find capital even in challenging times. This experience continues to shape our approach at Bayern Kapital and confirms the value of a long-term, sustainable investment strategy.

Bayern Kapital is considered one of the most financially strong state-backed VC investors in Germany, with investments of up to €50 million per company. How does this unique selling point contribute to Bavaria’s attractiveness as a location and for technology-oriented start-ups, such as those in the chemical industry?

The ability to support companies as an anchor investor over multiple financing rounds and commit investments of up to €50 million is a central unique selling point of Bayern Kapital—and a rarity in this combination across Europe. For technology-oriented and capital-intensive start-ups, particularly in the chemical industry or related deep tech sectors, this cross-phase financing perspective is crucial.
Our investments are deliberately tied to a relevant location in Bavaria. This creates a clear incentive to establish and develop innovative, high-growth companies in the Free State. For start-ups, this means planning security and reliability across multiple financing rounds, while for Bavaria as a location, it strengthens the settlement of technologically demanding companies.
In this way, Bayern Kapital contributes to further enhancing Bavaria’s attractiveness and competitiveness as a location for international high-tech and deep tech companies.

Many chemical start-ups face long development cycles and high capital requirements. Where do you see the biggest stumbling blocks in financing—and how can Bayern Kapital provide concrete support?

The biggest challenges lie in the combination of high technological risk, significant capital intensity, and long development cycles. Many chemical start-ups require substantial investments over an extended period before reaching market maturity. At the same time, risk capital for such deep tech models remains limited in Europe. Additional location-specific challenges, such as a difficult market environment in the European chemical industry, high energy prices, and complex regulatory requirements, further complicate financing decisions.
Bayern Kapital can provide concrete support on several levels. As a long-term investor, we bring the necessary patience and are not focused on short-term success. Furthermore, we have a robust network of national and international co-investors that we can activate for follow-on financing.
Additionally, we support companies through our network in Bavaria’s innovation ecosystem—for example, by connecting them with initiatives like the ChemieCluster Bayern—also addressing location-specific issues. In this way, we help integrate financing, scaling, and location development, anchoring chemical start-ups in Bavaria for the long term.

What criteria are decisive for you when deciding whether to invest in a start-up?

Several factors are relevant here:

  • Who are the people behind the company? Is the team complementarily structured, and are the key positions filled?
  • Is the market sufficiently large, and does a competitive advantage exist?
  • What is the central unique selling point?
  • What does the IP portfolio look like? Are the essential intellectual property rights secured within the company or through licenses?
  • Will the company be adequately funded with this financing round to achieve key development milestones that enable follow-on financing or market entry?
  • Is the consortium capable of follow-on investment?

Looking ahead, which technological trends do you believe will most strongly shape the investment landscape in the coming years?

In the coming years, AI-driven technologies, data infrastructure, and automation will dominate the investment landscape, complemented by cybersecurity, sustainability technologies, and new hardware/cloud architectures. For investors, this means capital will increasingly flow into scalable platforms that connect data, AI, and physical systems (such as robots and edge devices), often structurally supported by regulation (e.g., the EU AI Act, ESG rules). In the chemical industry, investments will shift significantly toward digitalizing production, sustainable raw materials/processes, and new (bio)chemical solutions.

Dr. Nathalie Weitemeyer about herself:

I studied chemistry at the University of Tübingen and completed my PhD in the research group of Prof. Ernst Bayer, focusing on the synthesis and characterization of nanoparticles. After finishing my doctorate, I gained my first professional experience at Actipac GmbH, a start-up developing drug delivery systems. At the same time, I completed my postgraduate degree as a Business Chemist.
In 2001, I moved from the start-up sector into the investment field and joined Bayern Kapital GmbH. There, I supported companies from a wide range of industries and at different stages of development. In recent years, as Investment Director Life Sciences and Senior Investment Manager, I have focused primarily on life sciences, while continuing to take an interest in cases from other sectors as well.